Fund overview

The Fund’s investment objective is to seek long-term growth of capital by investing primarily in equity securities of companies located anywhere in the world and selected for their growth potential.

The Fund will invest primarily in securities of companies that have a life sciences orientation. Companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. The Fund will invest at least 25% of its total assets, in the aggregate, in the following industry groups: health care; pharmaceuticals; agriculture; cosmetics/personal care; and biotechnology. No more than 10% of the net asset value of the Fund may be invested in securities traded on any one developing market and the aggregate amount of the Fund which may be invested in securities traded on the developing markets is 20% of the net asset value of the Fund.


Why consider the fund?
Finding growth in health care

In addition to the powerful demographic trends affecting the sector, health care is also experiencing acceleration in innovation. The fund seeks to invest in growth companies that are addressing unmet medical needs or making the health care system more efficient and affordable.

Dedicated sector experts

Our dedicated team of analysts has more than 100 years of combined experience investing in health care companies. In this complex and rapidly growing sector, we believe it is critical to have an experienced team that seeks to understand both the science and the business of the companies in which they invest.

Deep and disciplined

We believe the combination of deep fundamental research and disciplined portfolio construction will lead to consistently strong results relative to both the health care sector and the broader equity market. The fund is balanced across the subsectors of health care and diversified across market-cap segments and geographies.


Andy Acker Portrait

Andy Acker, CFA

Fund Manager since 2007

Industry since 1996

Ethan Lovell Portrait

Ethan Lovell

Fund Manager since 2016

Industry since 1994

Effective 12 January 2016, Ethan Lovell joined Andy Acker as Co-Portfolio Managers of the Janus Global Life Sciences Fund.

Past performance is no guarantee of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This is not a solicitation for the sale of shares and nothing herein is intended to amount to investment advice.